絞り込み

17054

広告

Novel HldE-K Inhibitors Leading to Attenuated Gram Negative Bacterial Virulence.

著者 Desroy N , Denis A , Oliveira C , Atamanyuk D , Briet S , Faivre F , Lefralliec G , Bonvin Y , Oxoby M , Escaich S , Floquet S , Drocourt E , Vongsouthi V , Durant L , Moreau F , Verhey TB , Lee TW , Junop MS , Gerusz V
J Med Chem.2013 Feb 14 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Medicinal Chemistry and ‡Biology, Mutabilis , 102 Avenue Gaston Roussel, 93230 Romainville, France.

スターを付ける スターを付ける     (6view , 0users)

Full Text Sources

Medical

Molecular Biology Databases

We report here the optimization of an HldE kinase inhibitor to low nanomolar potency, which resulted in the identification of the first reported compounds active on selected E. coli strains. One of the most interesting candidates, compound 86, was shown to inhibit specifically bacterial LPS heptosylation on efflux pump deleted E. coli strains. This compound did not interfere with E. coli bacterial growth (MIC > 32 μg/mL) but sensitized this pathogen to hydrophobic antibiotics like macrolides normally inactive on Gram-negative bacteria. In addition, 86 could sensitize E. coli to serum complement killing. These results demonstrate that HldE kinase is a suitable target for drug discovery. They also pave the way toward novel possibilities of treating or preventing bloodstream infections caused by pathogenic Gram negative bacteria by inhibiting specific virulence factors.
PMID: 23409840 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード